This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Konrad MW , Dewitt SK , Bradley EC , Goodman G , Groves EC , Hersh EM , Krigel RL , Rudolph A
Interferon-Gamma Induced by Administration of Recombinant Interleukin-2 to Patients with Cancer - Kinetics, Dose Dependence, and Correlation with Physiological and Therapeutic Response
Journal of Immunotherapy. 1992 Jul;12(1) :55-63
AbstractThe administration of recombinant interleukin-2 as an i.v. bolus at dose levels of from 1 to 30 MIU/m2 to patients with cancer induces easily measurable serum interferon-gamma levels of 1 to 500 U/ml. After a lag of 1 h, interferon-gamma rises to a maximum at 4 h and then slowly decreases. The peak values are poorly correlated with the dose of interleukin-2, and thus must be also be dependent on other factors. Successive administration of interleukin-2 typically increases the peak level of interferon-gamma fourfold, but does not diminish the lag period. Peak levels of interferon-gamma are also increased by concurrent administration of interferon-beta with interleukin-2. Continuous i.v. infusion of 1.5 to 20 MIU/m2 of interleukin-2/day results in interferon-gamma levels of 1 to 7 U/ml. Hypotension, which is characteristically associated with interleukin-2 administration, is correlated with interferon- gamma levels in only some patients. There was no apparent correlation between tumor regression and serum interferon-gamma levels.
NotesEnglish Article HZ096 J IMMUNOTHER